Full Press Release Details
IDEAYA Announces Top Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ 11 Cutaneous Melanoma, and Synthetic Lethality Pipeline.
IDYA
IDEAYA Announces Top Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ 11 Cutaneous Melanoma, and Synthetic Lethality Pipeline
Key Takeaway: IDEAYA Announces Top Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ 11 Cutaneous Melanoma, and Synthetic Lethality Pipeline
Price reaction · baseline $25.29 (2023-10-20 close) · 4 other IDYA headline(s) in the window, move may be shared
day 0 close
+5.5%
day 1 · peak
+7.8%
day 3
+7%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma